JP2017535614A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535614A5
JP2017535614A5 JP2017545870A JP2017545870A JP2017535614A5 JP 2017535614 A5 JP2017535614 A5 JP 2017535614A5 JP 2017545870 A JP2017545870 A JP 2017545870A JP 2017545870 A JP2017545870 A JP 2017545870A JP 2017535614 A5 JP2017535614 A5 JP 2017535614A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkylene
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017545870A
Other languages
English (en)
Japanese (ja)
Other versions
JP7224102B2 (ja
JP2017535614A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/062017 external-priority patent/WO2016081918A1/en
Publication of JP2017535614A publication Critical patent/JP2017535614A/ja
Publication of JP2017535614A5 publication Critical patent/JP2017535614A5/ja
Priority to JP2022171339A priority Critical patent/JP2023011731A/ja
Application granted granted Critical
Publication of JP7224102B2 publication Critical patent/JP7224102B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017545870A 2014-11-21 2015-11-20 疾患治療用の縮合二環式化合物 Active JP7224102B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022171339A JP2023011731A (ja) 2014-11-21 2022-10-26 疾患治療用の縮合二環式化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462083031P 2014-11-21 2014-11-21
US62/083,031 2014-11-21
PCT/US2015/062017 WO2016081918A1 (en) 2014-11-21 2015-11-20 Fused bicyclic compounds for the treatment of disease

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020125592A Division JP2021011482A (ja) 2014-11-21 2020-07-22 疾患治療用の縮合二環式化合物
JP2022171339A Division JP2023011731A (ja) 2014-11-21 2022-10-26 疾患治療用の縮合二環式化合物

Publications (3)

Publication Number Publication Date
JP2017535614A JP2017535614A (ja) 2017-11-30
JP2017535614A5 true JP2017535614A5 (enExample) 2018-12-27
JP7224102B2 JP7224102B2 (ja) 2023-02-17

Family

ID=56014622

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017545870A Active JP7224102B2 (ja) 2014-11-21 2015-11-20 疾患治療用の縮合二環式化合物
JP2020125592A Pending JP2021011482A (ja) 2014-11-21 2020-07-22 疾患治療用の縮合二環式化合物
JP2022171339A Pending JP2023011731A (ja) 2014-11-21 2022-10-26 疾患治療用の縮合二環式化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020125592A Pending JP2021011482A (ja) 2014-11-21 2020-07-22 疾患治療用の縮合二環式化合物
JP2022171339A Pending JP2023011731A (ja) 2014-11-21 2022-10-26 疾患治療用の縮合二環式化合物

Country Status (17)

Country Link
US (5) US10233187B2 (enExample)
EP (1) EP3221321B1 (enExample)
JP (3) JP7224102B2 (enExample)
KR (1) KR20170117020A (enExample)
CN (2) CN107207513B (enExample)
AU (2) AU2015349687B2 (enExample)
CA (1) CA2968434A1 (enExample)
CL (1) CL2017001289A1 (enExample)
CO (1) CO2017005784A2 (enExample)
ES (1) ES2911293T3 (enExample)
IL (1) IL252309B (enExample)
MX (1) MX370480B (enExample)
MY (1) MY192927A (enExample)
RU (1) RU2706007C2 (enExample)
SA (1) SA517381566B1 (enExample)
SG (2) SG11201703953WA (enExample)
WO (1) WO2016081918A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
LT3177612T (lt) 2014-08-04 2022-06-10 Nuevolution A/S Pirimidino dariniai, pakeisti pasirinktinai kondensuotu heterociklilu, tinkami uždegiminių, metabolinių, onkologinių ir autoimuninių ligų gydymui
SG11201703953WA (en) * 2014-11-21 2017-06-29 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
SG10201908881PA (en) * 2015-03-26 2019-11-28 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
KR20190040936A (ko) * 2016-05-25 2019-04-19 아카나 테라퓨틱스, 엘티디. 파르네소이드 x 수용체 (fxr) 조정제와의 조합 요법
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
ES2921432T3 (es) 2016-06-13 2022-08-25 Gilead Sciences Inc Derivados de azetidina como moduladores de FXR (NR1H4)
EP4424364B1 (en) 2017-03-28 2026-01-21 Gilead Sciences, Inc. Combinations for use in the treatment of cirrhosis and liver fibrosis
TW201910332A (zh) * 2017-06-02 2019-03-16 英商艾卡那治療有限公司 稠合的雙環化合物
PE20211907A1 (es) 2019-01-15 2021-09-28 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
KR102725082B1 (ko) 2019-02-19 2024-11-04 길리애드 사이언시즈, 인코포레이티드 Fxr 효능제의 고체 형태
CN111825653A (zh) * 2019-04-19 2020-10-27 安道麦马克西姆有限公司 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途
EP4003350A1 (en) 2019-07-23 2022-06-01 Novartis AG Treatment comprising fxr agonists
CA3142905A1 (en) 2019-07-23 2021-01-28 Novartis Ag Combination treatment of liver diseases using fxr agonists
US20220340668A1 (en) 2019-09-03 2022-10-27 Novartis Ag Treatment of liver disease or disorder comprising actrii receptor antagonists
WO2021053618A1 (en) 2019-09-19 2021-03-25 Novartis Ag Treatment comprising fxr agonists
JP2022550312A (ja) 2019-09-30 2022-12-01 ノバルティス アーゲー Fxrアゴニストの使用を含む処置
JP2023507364A (ja) 2019-12-20 2023-02-22 ノバルティス アーゲー インテグリン阻害剤を使用する肝疾患の治療の組み合わせ
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
TWI872177B (zh) 2019-12-20 2025-02-11 丹麥商紐韋盧森公司 對核受體具有活性之化合物
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
TW202227405A (zh) * 2020-08-24 2022-07-16 以色列商安道麥馬克西姆有限公司 用於製備經取代的吡唑之方法
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
JP4679517B2 (ja) * 2003-07-23 2011-04-27 エグゼリクシス, インコーポレイテッド 薬剤としてのアゼピン誘導体
MXPA06003150A (es) 2003-09-17 2006-08-31 Johnson & Johnson Compuestos heterociclicos fusionados.
US20090137554A1 (en) * 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
US20090215748A1 (en) * 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
WO2010036362A1 (en) 2008-09-26 2010-04-01 Wyeth 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
US8252826B2 (en) 2010-03-24 2012-08-28 Hoffmann-La Roche Inc. Cyclopentyl- and cycloheptylpyrazoles
SG11201703953WA (en) * 2014-11-21 2017-06-29 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
JP2019520335A (ja) * 2016-05-25 2019-07-18 アカーナ・セラピューティクス・リミテッドAkarna Therapeutics, Ltd. 疾患治療用の縮合二環式化合物

Similar Documents

Publication Publication Date Title
JP2017535614A5 (enExample)
JP2018537413A5 (ja) 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物
JP2015522650A5 (enExample)
JP2016505614A5 (enExample)
JP2016540742A5 (enExample)
JP2015537020A5 (enExample)
JP2017538773A5 (enExample)
JP2016503799A5 (enExample)
JP2016531121A5 (enExample)
JP2017503833A5 (enExample)
JP2017519781A5 (enExample)
JP2016516043A5 (enExample)
JP2016514159A5 (enExample)
JP2015024998A5 (enExample)
JP2014503574A5 (enExample)
JP2015517574A5 (enExample)
JP2012092103A5 (enExample)
JP2014500861A5 (enExample)
JP2018528261A5 (enExample)
JP2017504635A5 (enExample)
JP2018516904A5 (enExample)
JP2019500387A5 (enExample)
JP2017501237A5 (enExample)
RU2016110096A (ru) Новое хинолин-замещенное соединение
JP2017523152A5 (enExample)